Join our webinar!

How Can Precision Medicine, Genetic Testing, and Biomarkers Support Better Healthcare Decisions?

18 June 2026 | 9:00–10:00 CET

Join us for an ASCERTAIN webinar exploring how genetic testing and biomarker profiling are transforming healthcare. These technologies are enabling more personalised treatment strategies, particularly in cancer care. At the same time, they raise important questions about evidence generation, affordability, reimbursement, and implementation in healthcare systems.

This webinar will examine the role of biomarkers and genetic testing from a health economics and health technology assessment (HTA) perspective. Speakers will discuss current challenges and opportunities related to cost-effectiveness, budget impact, reimbursement decision-making, and the integration of precision medicine into healthcare systems.

Drawing on research and experiences from the ASCERTAIN project, the session will highlight how transparent and adaptable modelling approaches can support access to innovative health technologies.

Microsoft Teams Link

The webinar will be hosted on Microsoft Teams.

Contact

If you have any questions about the webinar, please contact Eline Aas at on.oiu.nisidem@saa.enile

Contributors

Eline Aas
Eline Aas is Professor at the Department of Health Management and Health Economics at the University of Oslo and holds a joint position at the Norwegian Institute of Public Health. Her research focuses on health economic evaluations, decision-analytic modelling, register data analysis, and precision cancer medicine. She has extensive experience evaluating innovative healthcare interventions across several clinical areas.

Benjamin Peter Geisler
Benjamin Peter Geisler is a Doctoral Research Fellow at the Department of Health Management and Health Economics at the University of Oslo. His work focuses on health economic analysis and the evaluation of innovative health technologies.

Kine Pedersen
Kine Pedersen is Associate Professor at the Department of Health Management and Health Economics at the University of Oslo. Her work focuses on economic evaluation of healthcare interventions, disease simulation modelling, prevention and screening, and precision cancer medicine. She also teaches courses in economic evaluation and research design.

Mirjana Huic
Mirjana Huic is a medical doctor and specialist in clinical pharmacology and toxicology with extensive experience in health technology assessment (HTA). She has contributed to numerous EUnetHTA collaborations and European HTA reports covering a broad range of health technologies. She currently works as an independent HTA specialist and expert for several European health initiatives.